Leading pharmaceutical innovation

Mehr zum Buch

Pharmaceutical giants have doubled their investments in drug development in the past decade only to see new drug approvals remain constant. This book investigates and highlights a set of proactive strategies aimed at generating sustainable competitive advantage based on value-generating business practices. We focus on three sources of pharmaceutical innovation: new management methods in the drug development pipeline, new technologies as enablers for cutting-edge R& D, and new forms of cooperation and internationalization, such as open innovation in the early phases of R& D. Our findings are illustrated by cases from Europe, the US, and Asia.